Three MS treatments will be considered for inclusion on the PBS at a PBAC meeting in March – nabiximols (Sativex), siponimod (Mayzent), ozanimod (Zeposia).
The results of two international phase III clinical trials looking at the safety and effectiveness of ozanimod (Zeposia)
MS Research Australia has awarded $2.4 million in MS research grants to 19 new projects as part of $4.1 million MS research commitment for 2020.
MS Research Australia has released the outcomes of the Pain in MS workshop hosted in October 2019 to identify gaps in research into MS-related pain.
MS Australia joins other disability peak organisations in welcoming the Tune Review that provides recommendations to improve the National Disability
Mixing business with charity is what the MS Angels do best, making a real impact on MS research.
In what comes as an extremely frustrating and disappointing blow for people with secondary progressive MS (SPMS) and
Associate Professor Kaylene Young and Professor Bruce Taylor are working towards new discoveries that may provide treatments to
The MS Research Australia biennial Progress in MS Research Conference was recently held in Melbourne. Over 150 MS
